Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.

Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, Dillner J, Sparén P, Sundström K.

PLoS One. 2015 Jul 28;10(7):e0134185. doi: 10.1371/journal.pone.0134185. eCollection 2015.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

3.

Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study.

Kreusch T, Wang J, Sparén P, Sundström K.

BMJ Open. 2018 Oct 2;8(10):e024477. doi: 10.1136/bmjopen-2018-024477.

4.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

5.

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.

6.

HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.

Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, Nicoll S, Robertson C.

Br J Cancer. 2016 Mar 1;114(5):576-81. doi: 10.1038/bjc.2015.473. Epub 2016 Jan 22.

7.

How does HPV vaccination status relate to risk perceptions and intention to participate in cervical screening? a survey study.

Hestbech MS, Gyrd-Hansen D, Kragstrup J, Siersma V, Brodersen J.

BMC Public Health. 2016 Aug 3;15:708. doi: 10.1186/s12889-016-3397-y.

8.

The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.

Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG.

J Epidemiol Community Health. 2017 Oct;71(10):954-960. doi: 10.1136/jech-2017-209113. Epub 2017 Jul 29.

PMID:
28756395
9.

Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study.

Kumakech E, Andersson S, Wabinga H, Musubika C, Kirimunda S, Berggren V.

BMC Womens Health. 2017 Jun 2;17(1):40. doi: 10.1186/s12905-017-0394-y.

10.

Mothers' screening histories influence daughters' vaccination uptake: an analysis of linked cervical screening and human papillomavirus vaccination records in the North West of England.

Spencer Nee Pilkington AM, Brabin L, Verma A, Roberts SA.

Eur J Cancer. 2013 Apr;49(6):1264-72. doi: 10.1016/j.ejca.2012.12.001. Epub 2013 Jan 2.

PMID:
23290788
11.

Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16-28 years.

Jayasinghe Y, Rangiah C, Gorelik A, Ogilvie G, Wark JD, Hartley S, Garland SM.

J Clin Virol. 2016 Mar;76 Suppl 1:S74-S80. doi: 10.1016/j.jcv.2015.10.026. Epub 2015 Nov 4.

PMID:
26589584
12.
13.

Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.

Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, Svenson LW, Yang H.

CMAJ. 2016 Sep 6;188(12):E281-8. doi: 10.1503/cmaj.151528. Epub 2016 Jul 4.

14.

Does the HPV vaccination programme have implications for cervical screening programmes in the UK?

Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S.

Vaccine. 2014 Apr 1;32(16):1828-33. doi: 10.1016/j.vaccine.2014.01.087. Epub 2014 Feb 13.

15.

Associations between prior HPV4 vaccine doses and cervical cancer screening participation.

Boone SD, Pinkston CM, Baumgartner KB, Baumgartner RN, Harper SM, Bonham AJ, Paynter CA, Harper DM.

Cancer Epidemiol. 2016 Jun;42:108-14. doi: 10.1016/j.canep.2016.04.003. Epub 2016 Apr 18.

PMID:
27100836
16.

Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.

Castanon A, Landy R, Pesola F, Windridge P, Sasieni P.

Lancet Public Health. 2018 Jan;3(1):e34-e43. doi: 10.1016/S2468-2667(17)30222-0. Epub 2017 Dec 19.

17.

Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands.

Mollers M, Lubbers K, Spoelstra SK, Weijmar-Schultz WC, Daemen T, Westra TA, van der Sande MA, Nijman HW, de Melker HE, Tami A.

BMC Public Health. 2014 Mar 28;14:288. doi: 10.1186/1471-2458-14-288.

18.

Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.

Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L.

Int J Cancer. 2016 Jun 15;138(12):2867-74. doi: 10.1002/ijc.30035. Epub 2016 Mar 9. Erratum in: Int J Cancer. 2017 Jul 1;141(1):E1-E4.

19.

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.

Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK.

J Natl Cancer Inst. 2014 Mar;106(3):djt460. doi: 10.1093/jnci/djt460. Epub 2014 Feb 19.

PMID:
24552678
20.

Supplemental Content

Support Center